8-K: Quoin Pharmaceuticals Secures FDA Clearance for Second Pivotal Netherton Syndrome Study, Paving Way for Broader QRX003 Label

Quoin Pharmaceuticals Ltd. announced FDA clearance to initiate a second pivotal clinical study for its lead product QRX003 in Netherton Syndrome, aiming for a comprehensive data package to support broad regulatory approval.

Summary

• Quoin Pharmaceuticals Ltd. received FDA clearance to initiate CL-QRX003-002, a second pivotal clinical study for its lead product, QRX003, targeting Netherton Syndrome.
• This new study will evaluate QRX003 as a whole-body topical application in conjunction with off-label systemic therapy in approximately 12-15 subjects, covering at least 80% of their body surface area.
• The study complements the ongoing CL-QRX003-003 pivotal study, led by Dr. Amy Paller at Northwestern University, which tests QRX003 as monotherapy.
• Combined, both studies are expected to recruit between 24-30 subjects across 6 U.S. sites (5 currently open, 6th opening in June) and up to 6 international sites.
• Quoin anticipates completing recruitment for both pivotal studies by the end of Q1 2026 and filing a New Drug Application (NDA) for regulatory approval later in 2026.
• QRX003 is a topical lotion containing a broad-spectrum serine protease inhibitor, which has shown significant downregulation of kallikrein hyperactivity, leading to rapid skin healing, reduced pruritus, and improved sleep in previous studies.

Sentiment

Score: 9

Explanation: The announcement is overwhelmingly positive, detailing a significant regulatory milestone (FDA clearance for a second pivotal study), strategic expansion of the clinical program, and clear timelines for potential market entry. The company highlights its unique position in the Netherton Syndrome treatment landscape and positive prior clinical data, with no apparent negative news or delays.

Positives

• Received FDA clearance for a second pivotal clinical study (CL-QRX003-002) for QRX003 in Netherton Syndrome, a significant regulatory milestone.
• The new study design (whole-body application with adjunct therapy) complements the existing monotherapy study, potentially leading to the broadest possible label opportunity post-approval for QRX003.
• Quoin is currently the only company conducting two late-stage whole-body pivotal clinical studies in Netherton Syndrome patients.
• Existing clinical data from earlier studies demonstrated clear evidence of rapid, prolonged, and almost complete skin healing, along with the elimination of key symptoms like chronic pruritus and sleep disturbances.
• Five U.S. clinical sites are already open, and six international sites are in advanced stages of preparation, with available cohorts of subjects ready for enrollment, facilitating accelerated recruitment.
• Anticipated completion of recruitment by end of Q1 2026 and NDA filing later in 2026 indicates a clear and relatively near-term path to potential regulatory approval.

Risks

• The Company's ability to successfully pursue its regulatory strategy.
• The Company's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements.
• The Company's ability to complete clinical trials on time and achieve desired results and benefits as expected.
• Other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and in other SEC filings.

Future Outlook

Quoin Pharmaceuticals anticipates completing recruitment for both pivotal Netherton Syndrome studies (CL-QRX003-002 and CL-QRX003-003) by the end of Q1 2026 and plans to file a New Drug Application (NDA) for regulatory approval later in 2026. The combined data from these studies is expected to provide QRX003 with the broadest possible label opportunity post-approval, covering both monotherapy and adjunct therapy in conjunction with off-label systemic treatments. The company believes its pipeline products have the potential to target a broad number of rare and orphan indications.

Management Comments

• "I am very pleased to announce yet another important and significant milestone for Quoin."
• "With FDA clearance to conduct this study, Quoin is the only company conducting two late-stage whole-body pivotal clinical studies in Netherton Syndrome patients."
• "We believe that the combined data generated from Study CL-QRX003-003, where, QRX003 is being administered as monotherapy and this study, CL-QRX003-002, where QRX003 is being tested in conjunction with off-label systemic therapy, has the potential to generate a highly comprehensive safety and efficacy data package that could support the regulatory approval of a treatment for this dreadful disease."

Industry Context

This announcement positions Quoin Pharmaceuticals as a significant player in the rare and orphan disease space, specifically for Netherton Syndrome. The FDA clearance for a second pivotal study, especially one exploring adjunct therapy, indicates a strategic approach to maximize market potential and address diverse patient needs within this severe genetic skin disorder. Being the only company with two late-stage whole-body pivotal studies for Netherton Syndrome suggests a leadership position in this niche, potentially accelerating the path to market for QRX003 and offering a much-needed treatment option for patients with high unmet medical needs.

Stakeholder Impact

• Shareholders: Positive impact due to significant progress in the clinical development of the lead product, potentially increasing the likelihood and speed of market approval and future revenue.
• Patients (Netherton Syndrome): Highly positive impact as QRX003 could offer a much-needed, effective treatment option for a severe, rare disease, potentially improving quality of life by reducing symptoms like skin shedding and pruritus.
• Employees: Positive impact due to continued progress and stability of the company's core development programs.
• Regulatory Authorities (FDA): The clearance indicates continued collaboration and adherence to regulatory requirements.

Next Steps

• Open the sixth U.S. clinical site for the pivotal studies in June.
• Complete recruitment into both pivotal studies (CL-QRX003-002 and CL-QRX003-003) by the end of Q1 2026.
• File a New Drug Application (NDA) for regulatory approval later in 2026.

Key Dates

Recommendation

Keywords

Quoin Pharmaceuticals, Netherton Syndrome, QRX003, FDA clearance, clinical trial, pivotal study, rare disease, orphan disease, dermatology, serine protease inhibitor, topical lotion, biotechnology, pharmaceuticals